Navigation Links
Seeing Alzheimer's amyloids

In an important step toward demystifying the role protein clumps play in the development of neurodegenerative disease, researchers have created a stunning three-dimensional picture of an Alzheimers peptide aggregate using electron microscopy. The study, in this weeks issue of the Proceedings of the National Academy of Sciences, reports that researchers from Brandeis University in Waltham, Mass., and the Leibniz Institut in Jena, Germany, have shownfor the first timehow A-beta peptide, found in the brains of Alzheimers patients, forms a spaghetti-like protein mass called an amyloid fibril.

This study is a significant advance regarding our understanding of how these fibrils are built from the A-beta peptide (Alzheimer's peptide), said co-author Nikolaus Grigorieff, a biophysicist at Brandeis University and an investigator with the Howard Hughes Medical Institute. People have been guessing for decades what these fibrils look like, but now we have an actual 3D image.

In healthy people A-beta peptide does not aggregate, but in Alzheimers patients it clumps first and then forms long fibrils, like tentacles, in a so-called cross-beta structure. Scientists disagree whether it is the clumps that kill neurons in the brain or the fibrils. Grigorieff wants to discover which part of the amyloid structure is toxic; that would be an important step in designing drugs to prevent or treat disease.

Amyloid structurethe particular way a protein or peptide clumps togetheris linked to other neurodegenerative conditions as well, including Parkinsons and Creutzfeldt-Jakob disease. The amyloid way of folding and aggregation seems to be a fundamental property of proteins and peptides explained Grigorieff. We know how most normal proteins fold, but what drives amyloid formation?

Its a question that has dogged structural biologists and biochemists for a long time but stubbornly refuses elucidation. Researchers using x-ray crystallography have so far been unable to obtain crystals from fibrils of full-length polypeptide chains. Structural models based on NMR data have also come up short. Scientists have made do with studying fragments of the A-beta peptide. The major barrier to determining the structure of A-beta fibrils is that the same peptide will exasperatingly assemble differently from fibril to fibrilunlike normal proteins, which reliably fold up the same way every time.

Grigorieff and his colleagues overcame this barrier by generating fibrils in a test tube under conditions that reduce the variability between fibrils, and by selecting about 200 images of fibrils that were most similar to each other and averaging them on a computer.

An expert at high resolution electron cryo-microscopy of protein complexes and macromolecular machines, Grigorieff said his lab made an image of the A-beta fibril at a resolution of eight Angstroms, revealing useful detail at a magnification of roughly a million times. Short of atomic resolution by a factor of 2.5 to 3, the image revealed how the peptide, a series of linked amino acids, was arranged in the tape-like fibril.

The next step will be a 3-D image that tells us exactly where all the amino acids are, postulates Grigorieff. This will tell us more about the chemical and biological properties of A-beta fibrils that we need to know to understand their role in Alzheimers.


Contact: Laura Gardner
Brandeis University

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
Post Your Comments:
Related Image:
Seeing Alzheimer's amyloids
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: